MicroPort Scientific Executive and Leadership Team

Martin Sun, the Chief Financial Officer at MicroPort Scientific, manages the global fiscal strategy and capital allocation for the organization. Sun oversees financial reporting, treasury operations, and investor relations, ensuring transparency and long-term economic stability. By analyzing market trends across diverse geographic regions, the Chief Financial Officer aligns investment priorities with the overarching mission of expanding medical device access. Martin Sun coordinates with the Board to evaluate potential acquisitions and strategic partnerships that enhance the corporate portfolio. This leadership role involves maintaining robust internal controls and optimizing tax structures to support sustainable growth. Through precise financial forecasting and risk management, the Chief Financial Officer provides the necessary resources for R&D and manufacturing expansion. Ultimately, Sun secures the financial health required to support the ongoing development of life-saving medical technologies on a global scale.

Caesar Fonte, the President at MicroPort Scientific, directs the commercial operations and market expansion strategies for the Americas. Fonte oversees the sales and marketing divisions, ensuring that high-quality medical devices reach healthcare providers efficiently. By analyzing regional market dynamics, the President optimizes distribution networks and strengthens relationships with key clinical stakeholders. Caesar Fonte coordinates with the executive team to implement growth initiatives that increase market share in the competitive medical device landscape. This leadership role involves managing regional performance metrics and ensuring that commercial activities align with corporate quality standards. Through the execution of targeted business development plans, the President drives revenue growth and enhances brand presence across the Western Hemisphere. Ultimately, Fonte supports the company's mission by ensuring that advanced medical treatments are readily available to patients and surgeons throughout the region.

Philippe Wanstok, the President at MicroPort Scientific, manages the strategic operations and business development initiatives across the EMEA region. Wanstok oversees the integration of local market requirements into the global product strategy, ensuring that medical devices meet specific regulatory and clinical needs. By fostering partnerships with healthcare institutions and distributors, the President expands the reach of the company's portfolio. Philippe Wanstok directs the implementation of regional sales strategies that prioritize patient outcomes and operational efficiency. This leadership role involves navigating complex healthcare environments and ensuring that the company remains a preferred partner for medical professionals. Through the oversight of regional performance and resource allocation, the President drives sustainable growth in diverse markets. Ultimately, Wanstok strengthens the company's international footprint by delivering high-quality medical solutions that improve the lives of patients across Europe, the Middle East, and Africa.

YiYong Sun, the President at MicroPort Scientific, directs the manufacturing excellence and supply chain operations within the Asia-Pacific region. Sun oversees the production facilities and logistics networks, ensuring that high-quality medical devices are manufactured to exact specifications. By implementing lean manufacturing principles and advanced automation, the President optimizes production capacity and reduces operational costs. YiYong Sun coordinates with quality assurance teams to maintain strict adherence to international safety standards across all manufacturing sites. This leadership role involves managing the end-to-end supply chain, from raw material procurement to final product distribution. Through the continuous improvement of manufacturing processes, the President supports the company's ability to scale production in response to global demand. Ultimately, Sun ensures the reliability and availability of critical medical devices, directly contributing to the company's mission of providing accessible healthcare solutions to patients.

Qiyi Luo, the Chief Technology Officer at MicroPort Scientific, directs the research and development of advanced medical device platforms. Luo oversees the engineering teams focused on cardiovascular and orthopedic innovation, ensuring technical excellence across all product lines. By integrating emerging materials science into current manufacturing processes, the Chief Technology Officer optimizes device performance for global clinical applications. Qiyi Luo maintains close collaboration with regulatory bodies to ensure compliance while accelerating the transition from prototype to market-ready solution. This leadership role involves managing complex R&D budgets and fostering a culture of continuous technical improvement. Through the implementation of rigorous testing protocols, the Chief Technology Officer guarantees that every product meets the highest safety standards. Ultimately, Luo drives the technological roadmap that sustains the competitive advantage of the company within the international medical device sector.

Tao Li, the Co-Founder & Chief Technology Officer at MicroPort Scientific, architects the foundational vision for next-generation medical device architecture. Li oversees the long-term innovation strategy, focusing on disruptive technologies that redefine patient care standards. By bridging the gap between clinical needs and engineering capabilities, the Co-Founder & Chief Technology Officer ensures that product development remains aligned with the core mission of longevity and health. Tao Li directs cross-functional teams in the exploration of minimally invasive surgical tools and smart implantable devices. This leadership role involves mentoring technical staff and establishing intellectual property strategies that protect the company's unique innovations. Through the application of advanced biomechanical research, the Co-Founder & Chief Technology Officer drives the evolution of the product pipeline. Ultimately, Li shapes the future trajectory of the company by championing breakthrough medical solutions that address unmet patient requirements.